Zentalis keeps the heat on AstraZeneca with early WEE1 data showing a group of 'exceptional' responders

Zentalis keeps the heat on AstraZeneca with early WEE1 data showing a group of 'exceptional' responders

Source: 
Endpoints
snippet: 

Zentalis’ WEE1 inhibitor, ZN-c3, posted partial responses across a slate of tumor types with a tolerable safety profile as monotherapy for solid tumor patients who are either treatment-resistant or have no established standard of care, according to interim Phase I data presented as a late breaker Saturday at the virtual AACR annual meeting.